NCT01839149View on ClinicalTrials.gov

TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions
High Frequency Episodic Migraine and Chronic Migraine
Interventions
DRUG

TI-001

TI-001 is intranasal oxytocin

DRUG

Placebo

Trial Locations (6)

Unknown

Fitzroy

Prahran

Sherwood

Santiago

Tauranga

Wellington

All Listed Sponsors
lead

Trigemina, Inc

INDUSTRY

NCT01839149 - TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine | Biotech Hunter | Biotech Hunter